#1 Clinical Trials Search in Europe

Tezepelumab

Tezepelumab is an emerging biologic therapy being studied in clinical trials for the treatment of severe asthma. This article summarizes key findings from recent trials evaluating the efficacy and safety of tezepelumab in patients with inadequately controlled severe asthma. The trials examine outcomes such as asthma exacerbations, lung function, quality of life, and potential effects on the immune system.

Table of Contents

What is Tezepelumab?

Tezepelumab is a new medication that has shown promising results in treating severe asthma and other conditions. It is known by several names, including AMG 157 and MEDI9929[1]. Tezepelumab is a type of drug called a monoclonal antibody, which is a laboratory-made protein that mimics the immune system’s ability to fight off harmful pathogens like viruses[2].

How Does Tezepelumab Work?

Tezepelumab works by targeting a specific protein in the body called thymic stromal lymphopoietin (TSLP). TSLP is believed to play an important role in starting and continuing airway inflammation, which is a key factor in asthma and other respiratory conditions[3]. By blocking TSLP, tezepelumab can help reduce inflammation in the airways, making it easier for patients to breathe.

Conditions Treated with Tezepelumab

Tezepelumab is primarily used to treat severe asthma, but research is ongoing to explore its potential in treating other conditions. Here are the main conditions being studied:

  • Severe Asthma: Tezepelumab has been approved for treating severe asthma in adults and adolescents who have difficulty controlling their symptoms with other medications[1].
  • Eosinophilic Granulomatosis with Polyangiitis (EGPA): This is a rare blood vessel disease that can affect multiple organs, including the lungs. Researchers are studying whether tezepelumab can help patients with EGPA[4].
  • Atopic Dermatitis: Also known as eczema, this is a condition that causes dry, itchy skin. Studies are being conducted to see if tezepelumab can help improve symptoms of moderate-to-severe atopic dermatitis[5].

How is Tezepelumab Administered?

Tezepelumab is given as a subcutaneous injection, which means it’s injected just under the skin. The typical dose is 210 mg every 4 weeks[1]. In most cases, the injection is given by a healthcare professional at a clinic or hospital. However, some studies are exploring the possibility of patients or caregivers administering the medication at home after proper training[2].

Effectiveness of Tezepelumab

Clinical trials have shown that tezepelumab can be effective in reducing asthma symptoms and improving lung function in patients with severe asthma. Some of the benefits observed in studies include:

  • Reduction in asthma exacerbations (sudden worsening of asthma symptoms)[1]
  • Improvement in lung function tests, such as FEV1 (forced expiratory volume in 1 second)[1]
  • Better control of asthma symptoms, as measured by standardized questionnaires[1]
  • Reduction in the need for oral corticosteroids, which can have significant side effects when used long-term[1]

Ongoing Research and Future Potential

Researchers are continuing to study tezepelumab to better understand its effects and explore its potential in treating other conditions. Some ongoing areas of research include:

  • Using tezepelumab to treat asthma exacerbations in emergency room settings[2]
  • Investigating how tezepelumab affects the body’s immune response to flu vaccines[6]
  • Studying the long-term effects of tezepelumab on airway remodeling (structural changes in the airways) in asthma patients[7]
  • Exploring the potential of tezepelumab in treating allergic asthma and improving airway hyperresponsiveness (overly sensitive airways)[8]

Side Effects and Safety

As with any medication, tezepelumab can cause side effects. However, clinical trials have shown that it is generally well-tolerated. Common side effects may include:

  • Injection site reactions (redness, pain, or swelling where the injection was given)
  • Headache
  • Fatigue
  • Back pain

Long-term safety studies are ongoing to better understand the safety profile of tezepelumab over extended periods of use[9]. It’s important to discuss potential risks and benefits with your healthcare provider before starting any new medication.

Aspect Details
Drug Name Tezepelumab
Mechanism of Action Blocks thymic stromal lymphopoietin (TSLP)
Administration Subcutaneous injection, 210 mg every 4 weeks
Primary Outcomes Reduced asthma exacerbations, improved lung function (FEV1)
Secondary Outcomes Improved quality of life, reduced oral corticosteroid use
Target Population Patients with severe, inadequately controlled asthma
Safety Profile Generally well-tolerated, common side effects include headache and nasopharyngitis
Ongoing Research Effects on airway remodeling, immune response to vaccines

FAQ

  • What is tezepelumab and how does it work? Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine involved in airway inflammation. By targeting TSLP, tezepelumab aims to reduce inflammation and improve asthma control in patients with severe asthma.
  • What are the main benefits of tezepelumab observed in clinical trials? Clinical trials have shown that tezepelumab can reduce asthma exacerbations, improve lung function, and enhance quality of life in patients with severe asthma. It has demonstrated efficacy across different types of severe asthma, regardless of specific biomarkers.
  • How is tezepelumab administered? Tezepelumab is administered as a subcutaneous injection, typically given every 4 weeks. The standard dose studied in most trials is 210 mg.
  • What are the potential side effects of tezepelumab? The most common side effects observed in clinical trials include headache, nasopharyngitis, and injection site reactions. Overall, tezepelumab has demonstrated a favorable safety profile in studies.
  • Who might benefit from tezepelumab treatment? Tezepelumab may benefit patients with severe asthma who have inadequate control despite using high-dose inhaled corticosteroids and additional controller medications. It has shown efficacy in patients with both eosinophilic and non-eosinophilic asthma.

Ongoing Clinical Trials on Tezepelumab

  • Study of Tezepelumab Compared to Placebo in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark Germany Italy Poland Slovakia +1

  • Study of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Denmark France Greece Hungary +3

  • Study on Symptom Changes in Adults with Chronic Rhinosinusitis with Nasal Polyps Using Tezepelumab

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria France Germany Hungary Italy Poland +1

  • Study of Tezepelumab effects on airway barrier function in patients with severe asthma, with or without chronic rhinosinusitis with nasal polyps

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study on Tezepelumab for Patients with Severe Asthma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of tezepelumab in patients with progressive pulmonary fibrosis and increased eosinophil levels in blood

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effects of Tezepelumab on Airway Inflammation in Patients with Chronic Obstructive Pulmonary Disease (COPD)

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Tezepelumab for Children Aged 5 to 11 with Severe Asthma

    Recruiting

    1 1 1
    Investigated drugs:
    France Hungary Italy The Netherlands Poland Romania +1

  • Study on Reducing Asthma Medication with Tezepelumab in Patients Aged 12 to 80 with Severe Asthma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Denmark France Germany Italy +1

  • Efficacy of Tezepelumab in Treating Bronchiolitis Obliterans Syndrome in Allogeneic Stem Cell Transplant Recipients

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Tezepelumab: A monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), used in the treatment of severe asthma.
  • TSLP (Thymic Stromal Lymphopoietin): An epithelial cytokine involved in the initiation and continuation of airway inflammation in asthma.
  • Asthma exacerbation: A worsening of asthma symptoms that may require additional treatment, emergency care, or hospitalization.
  • FEV1 (Forced Expiratory Volume in 1 second): A measure of lung function that represents the volume of air exhaled in the first second of forced expiration.
  • ACQ-6 (Asthma Control Questionnaire-6): A validated questionnaire used to assess asthma control in clinical trials and practice.
  • Eosinophilic asthma: A type of asthma characterized by high levels of eosinophils, a type of white blood cell, in the airways.
  • Inhaled corticosteroids (ICS): Anti-inflammatory medications inhaled directly into the lungs to reduce airway inflammation in asthma.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to specific targets in the body, used in the treatment of various diseases including asthma.
  • Subcutaneous injection: An injection given into the fatty tissue just beneath the skin.
  • Biomarker: A measurable indicator of a biological state or condition, often used to predict or monitor response to treatment.

References

  1. https://clinicaltrials.gov/study/NCT05329194
  2. https://clinicaltrials.gov/study/NCT06705764
  3. https://clinicaltrials.gov/study/NCT06438913
  4. https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-tezepelumab-for-adults-with-eosinophilic-granulomatosis-with-polyangiitis-egpa/
  5. https://clinicaltrials.gov/study/NCT03809663
  6. https://clinicaltrials.gov/study/NCT05062759
  7. https://clinicaltrials.eu/trial/study-on-tezepelumab-for-patients-with-severe-asthma/
  8. https://clinicaltrials.gov/study/NCT05740748
  9. https://clinicaltrials.gov/study/NCT04048343